Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lanosterol 14-alpha demethylase, also known as CYP51, is a cytochrome P450 enzyme that plays a critical role in the biosynthesis of ergosterol, an essential component of fungal cell membranes. This enzyme catalyzes the oxidative removal of the 14α-methyl group from lanosterol through a three-step monooxygenation process. The resulting product is further processed to form ergosterol, which regulates membrane permeability and rigidity in fungi. It is the primary target for azole antifungals, and resistance can arise through amino acid substitutions or increased efflux pump activity.
Inhibition of lanosterol 14-alpha demethylase, leading to depletion of ergosterol and accumulation of toxic sterols.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lanosterol 14-alpha Demethylase (Fungal).